SUMMARY -Th ere is a small but well recognized group of patients with multiple myeloma (MM), characterized by multiple bone lesions and low tumor burden, the so-called macrofocal form of MM (MF-MM). Th e aim of the study was to analyze the incidence, clinical manifestation, therapeutic outcome and prognosis of patients with MF-MM treated with bortezomib-based therapy and radiotherapy, in comparison to classic MM. Th ere were 148 MM patients treated with bortezomibbased regimens, with 15 (10.1%) of them meeting the criteria for MF-MM. Comparative analysis involved disease-and therapy-related variables and markers of bone metabolism in MF-MM and classic MM groups. Event-free survival (EFS) and median survival (MS) were analyzed. Patients in MF-MM and classic MM groups had similar mean age and sex distribution. Patients with MF-MM had advanced myeloma bone disease (MBD), signifi cantly lower clonal plasma cell infi ltration in bone marrow, and lower paraprotein level. Th ese patients were predominantly in an early International Staging System stage, showed non-secretory and light-chain variants, and signifi cant association with extramedullary plasmacytomas. EFS was 20 months in MF-MM group versus 13 months in classic MM group (nonsignifi cant diff erence). MS was 42 months in both MF-MM and classic MM groups. MF-MM presents with imbalance of the minimal tumor burden and massive bone involvement. Along with advanced skeletal manifestations, these patients showed features of preserved bone marrow and no end-organ damages. Following bortezomib-based therapy and radiotherapy, the EFS and MS did not diff er between MF-MM and classic MM groups.
Introduction
Generalized bone lesions aff ect clinical evolution of multiple myeloma (MM), create diffi culties in defi ning the stage of the disease, its therapeutic outcome does not always follow the outcome of medullary disease, and myeloma bone disease (MBD) disables patients and deteriorates their prognosis. Usually, severe MBD refl ects an advanced MM with high percentage of bone marrow plasma cell infi ltration, high level of serum/urine paraprotein and end-organ damages.
A small proportion of MM patients present with multiple, generalized bone lesions and low tumor burden, i.e. low percentage of monoclonal plasma cells in bone marrow and low production of paraprotein or non-secretory variants. Th is group is called by some authors multifocal form of MM (MF-MM). Th e same term was used in our analysis. Th ere are limited data in the literature on therapeutic options, outcome, monitoring of therapeutic response, prognostic factors and survival of these patients.
Th e aim of the study was to analyze the incidence, clinical manifestation, therapeutic outcome and prognosis of patients with MF-MM treated with bortezomib-based therapy and radiotherapy in comparison to classic MM.
Patients and Methods
During the period from January 2008 till June 2014, 148 patients with MM treated with bortezomib-based regimens were retrospectively studied. Th eir mean age was 60.16±9.43 years and the male to female ratio was 1.05:1. Th e criteria for MF-MM were: MBD grade 2 and 3; clonal plasma cell infi ltration in bone marrow less than 20%; and paraprotein in serum <25g/L, paraprotein in urine <1.0 g/24 h by protein electrophoresis/immune fi xation. Fifteen of 148 (10.1%) patients fulfi lled the criteria for MF-MM (Table 1) . Clinical stage was defi ned according to the International Staging System (ISS). Bone lesions were assessed by conventional x-ray of axial skeleton or computed tomography (CT) scan and magnetic resonance imaging (MRI) at the sites of interest. MBD was graded in four grades: 0 -no lytic bone lesions or osteoporosis; 1 -osteolytic lesions at <3 sites +/-osteoporosis; 2 -multiple bone lesions at >3 sites and/or pathologic fractures; and 3 -multiple lytic lesions and destructions of skeletal segments. All 148 patients were treated with bortezomib-based regimens in 21-day cycles. Bortezomib (Millennium Pharmaceuticals, Inc., Th e Takeda Oncology Company, Cambridge, Massachusetts, USA) was administered in a dose of 1.3 mg/m 2 on days 1, 4, 8 and 11, and was combined with dexamethasone (VelDex) in 31 (20.9%), with cyclophosphamide (CyBorD) in 54 (36.5%) and with anthracycline (PAD) in 14 (9.5%) patients. Bortezomib regimen was administered as fi rst line therapy in 53 (36.1%), as second line therapy in 51 (34.7%) and as >second line therapy in 43 (29.1%) patients. Five (33.33%) patients underwent high-dose therapy with melphalan 200 mg/m 2 with autologous stem-cell transplantation. Radiotherapy of lytic bone lesions, pathologic factures and soft tissue plasmacytomas was incorporated in therapeutic regimen when indicated. Patients underwent radiotherapy on a linear accelerator Siemens Mevatron Primus. Two main schemes of irradiation were used: 2×8.5 Gy with an interval of 72 hours and 5×4 Gy. Th ree patients received irradiation at one of the aff ected sites with 1 fraction of 8 Gy as a single dose. Comparative analysis of the disease and therapy related variables and markers of bone metabolism (serum Ca and alkaline phosphatase, AP) was performed in patients with MF-MM and classic MM. As patients with MF-MM represent a unique problem in terms of therapeutic response because many of them lack a detectable monoclonal protein in serum and/or urine and myeloma cell infi ltration in bone marrow is initially low, the event free survival (EFS) and median survival (MS) were assessed for analysis of outcome. Th erapeutic response of MBD was assessed by the dynamics of bone pain, dynamics in the size of bone lesions and changes in the level of serum Ca and AP. Statistical analysis was performed by use of SPSS v. 18.0, using descriptive analysis, analysis of variation and analysis of alternatives, and independent samples T-test for independent samples. Th e method of Kaplan-Maier with log rank test was used for analysis of EFS and MS.
Results
Patients in the MF-MM and classic MM groups had similar mean age (60.6±7.32 vs. 60.11±9.67 years) and similar sex distribution (Table 2) .
Clinical characteristics of MF-MM patients in comparison to classic MM
By the principle of selection, in comparison with classic MM patients, all patients with MF-MM had 1 and 2 ). In the group of MF-MM, there were no patients with severe anemia, while the share of patients with renal failure, hypoalbuminemia and elevated beta 2 -microglobulin (β2M; >3.5 mg/L) was signifi cantly lower. MF-MM was signifi cantly associated with extramedullary plasmacytomas (Table 2) . Th e levels of hemoglobin and albumin were also signifi cantly higher, while β2M and creatinine were signifi cantly lower than in classic MM (Table 3) . Th ere was no betweengroup diff erence in the levels of Ca and AP.
Th erapeutic outcome
Th e mean number of bortezomib cycles was 6.07±1.06 in MF-MM and 6.73±0.49 in classic MM group (NS). Patients with MF-MM were irradiated signifi cantly more frequently than those with classic MM (14 (93.3%) vs. 65 (49.9%); p<0.001) and MF-MM had a signifi cantly higher mean number of irradiations (2.53±0.34 vs. 0.56±0.54; p<0.001). Th erapy alleviated bone pain in all patients, and in 9/15 patients complete resolution of symptoms occurred. In 3 patients, reduction in the size of bone lesions was observed. Extramedullary formations were reduced in all patients, and in 11/15 patients they completely disappeared (fi brous tissue on enhanced CT scan). After therapy, a signifi cant increase in the level of AP and decrease in the levels of Ca, LDH and β2M was recorded (Table 4) . Th ere was a trend of longer EFS of 20 months (95% confi dence interval (95% CI): 18.152-21.848) in MF-MM group versus 13 months (95% CI: 10.213-15.787) in classic MM group but the diff erence was not statistically signifi cant (Fig. 3) . MS was 42 months in both MF-MM and classic MM groups: MF-MM 95% CI: 18.38-65.62 and classic MM 95% CI: 37.04-46.96.
Toxicity
Th ere was no signifi cant diff erence in hematologic and non-hematologic toxicity between the two groups, although patients with MF-MM had undergone more irradiation (Table 5) . Th e most common side eff ect was peripheral polyneuropathy: 5 (33.3%) versus 46 (35.9%) in the MF-MM and classic MM group, respectively. Th ere were no patients with polyeuropathy grade 3 and 4.
Discussion
Intensive bone resorption is the earliest event in the evolution of MM 1 , while the increased number of osteoclasts/mm 2 per trabecular bone surface is the most solid marker of monoclonal gammopathy of undetermined signifi cance (MGUS) transformation into active MM 2 . Nowadays, the pathogenic mechanisms of bone resorption are a subject of profound research. Both the osteolytic lesions at the sites of plasma cell infi ltration and distant humoral demineralization of bone are a result of the action of osteolytic cytokines secreted or induced by myeloma cells. A great number of osteolytic substances or 'osteoclast activating factors' have been discussed in the literature, e.g., tumor necrosis factor α (TNF-α), TNF-β, interleukin 1b (IL-1b), IL-6, IL-10, IL-11, hepatocyte growth factor (HGF), matrix metalloproteinases (MMP) 2, 7, 9, and macrophage infl ammatory protein (MIP-1α, MIP-1β) 3 . Nowadays, the critical role of the osteoprotegerin/receptor activator of NF-jB ligand (OPG/RANKL) system in bone remodeling in physiologic and pathologic conditions and in MM has been proven in many preclinical settings and in myeloma patients. Th e balance of the system is shifted towards RANKL overexpression and OPG suppression resulting in increased bone resorption and decreased bone formation. Th e role of Dickkopf protein-1 (DKK-1) as an inhibitor of osteoblast function is also important [4] [5] [6] [7] . Th e negative quantitative balance of bone remodeling is a result of enhanced osteoclast function and suppressed osteoblast function refl ected by the level of bone-specifi c AP. Until the era of novel agents, almost all drugs attacked the factors responsible for osteoclast activation, and no drug stimulated osteoblast function. With the introduction of bortezomib in clinical practice, it was proven that proteasome inhibition not only suppresses bone resorption but also aff ects positively osteoblast function 8 . Th ere are data on a decrease of the markers of bone resorption and increase of the markers of bone synthesis in MM after treatment with bortezomib 9 . Patients with MF-MM present a specifi c feature, imbalance of the minimal tumor burden on the one hand, and massive bone involvement, i.e. multiple osteolytic lesions, fractures, and destructions of skeletal segments on the other hand. A parallel to light-chain (AL) amyloidosis is possible: in AL amyloidosis, low plasma cell tumor mass produces light chains with prominent tissue tropism; in MF-MM form, a higher expression of osteolytic cytokines with high bone impact is suspected. Although MF-MM form is rare, it poses signifi cant diffi culties in diagnosis, staging, prognostic assessment and therapy of patients. Th ese patients share some common characteristics such as low tumor burden, i.e. low percentage of clonal plasma cells in bone marrow, and low production of serum and/or urine paraprotein, with a predominance of the non-secretory and light-chain variants. Minimal suppression of hematopoiesis and low M-grade with rare immune paresis is refl ected by the unusual normal levels of hemoglobin 10 , platelets and β2M, and preserved renal function. Th e most prominent feature of MF-MM is massive involvement of skeleton and frequent associations with soft tissue plasmacytomas 11 . Th ere are contradictory data concerning the outcome of these patients. Smith et al. report that patients with non-secretory MM and multiple lytic bone lesions have a signifi cantly shorter MS of 21 months versus 42 months 12 . In a retrospective study, Dimopoulous et al. found the incidence of MF-MM of 10/56 in young MM patients for a 20-year period, therapeutic response rate of 55%, and unreached MS. According to the authors, these patients had low tumor burden and better outcome with calculated MS of 8 years 13 . Kumar et al. describe atypical presentations of non-secretory MM and their frequent association with multiple bone lesions and plasmacytomas. Th ey proved similar outcome and prognosis in these patients after autologous stem cell transplantation compared to the classic MM form 11 . Our patients shared the presenting features reported by most of the authors with identical MS in the two groups after therapy with bortezomibbased regimens and radiotherapy. Th e trend of longer PFS in our analysis may have been a refl ection of the late diagnosis of relapse due to the absence or low grade M-component. Th e dynamics of the bone metabolism markers of Ca and AP after therapy with bortezomib-based regimens plus radiotherapy refl ected improved osteoblast and osteoclast function. While the rapid therapeutic response and improvement in the markers of MM activity are typical after bortezomib therapy, there are few data on the reduction in the size of ostelytic bone lesions and increase in the bone fraction of AP. Zangari et al. found a 25% increase of AP level above the baseline, which correlated with high CR + PR rates and longer time to progression 14 . Heider et al. demonstrated signifi cant elevation of osteocalcin and bone fraction of AP in parallel to reduction of collagen cross-links 15 . Th e mechanisms of improvement of bone lesions once they occur are still under investigation. Nowadays, the role of MRI and positron emission tomography-CT (PET-CT) in the assessment of MF-MM is proven as they diff erentiate plasma cell infi ltration of bone marrow, osteolytic bone lesions and soft tissue plasmacytomas. Th ese are the recommended methods for monitoring therapeutic response, with exceptional signifi cance in non-secreto-ry MM, soft tissue plasmacytomas, as well as in the MF-MM group.
Myeloma tumor mass, transformed bone marrow microenvironment, multiple cell populations of osteoclasts, osteoblasts, osteocytes, stromal cells, endothelial cells, cell-to-cell interactions and humoral factors are being attacked with 'novel' agents. Hopefully, it is a matter of near future to disrupt the 'vicious circle' of MM, i.e. as MM is more active, bone resorption is more intensive, and vice versa.
